VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
177.65
-3.67 (-2.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close181.32
Open180.80
Bid0.00 x 800
Ask0.00 x 800
Day's Range177.59 - 180.99
52 Week Range136.50 - 194.92
Volume863,298
Avg. Volume1,151,866
Market Cap45.4B
Beta (3Y Monthly)1.84
PE Ratio (TTM)110.14
EPS (TTM)1.61
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est198.27
Trade prices are not sourced from all markets
  • 3 High-Reward Stocks From 3 Emerging Trends
    InvestorPlace3 days ago

    3 High-Reward Stocks From 3 Emerging Trends

    Today I want to tell you about three stocks, each in its own emerging trend, that have huge upside potential in the transformative years ahead. Gene editing is just what it sounds like. CRISPR Therapeutics (NASDAQ:CRSP) is one of the three leaders in the gene editing sector.

  • FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
    American City Business Journals4 days ago

    FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial

    CRISPR and Vertex were preparing to test the the ability of a new gene-editing technology, CRISPR/Cas9, in cutting out and replacing disease-causing snippets of DNA when the FDA placed the hold in May.

  • How Is Vertex Pharmaceuticals Positioned in October?
    Market Realist4 days ago

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies that treat cystic fibrosis. Vertex Pharmaceuticals has key collaboration agreements with CRISPR Therapeutics (CRSP) to develop treatments for underlying genetic causes of human diseases by using CRISPR-Cas9 technology. It also uses Moderna Therapeutics to develop mRNA (messenger ribonucleic acid) therapeutics for cystic fibrosis, BioAxone to evaluate VX-210 as a treatment for spinal cord injuries, and Parion Sciences to develop epithelial sodium channel inhibitors to treat pulmonary diseases.

  • A Look at Vertex Pharmaceuticals’ Operational Performance
    Market Realist4 days ago

    A Look at Vertex Pharmaceuticals’ Operational Performance

    How Is Vertex Pharmaceuticals Positioned in October? Vertex Pharmaceuticals’ (VRTX) cost of sales was $104.38 million in the second quarter of 2018 compared to $71.2 million in the second quarter of 2017. It incurred selling, general, and administrative expenses of $137.3 million in the second quarter of 2018 compared to $127.25 million in the second quarter of 2017.

  • What Vertex Pharmaceuticals’ Valuation Trend Indicates
    Market Realist4 days ago

    What Vertex Pharmaceuticals’ Valuation Trend Indicates

    In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.

  • Why CRISPR Therapeutics Stock Is Heading Higher Today
    Motley Fool5 days ago

    Why CRISPR Therapeutics Stock Is Heading Higher Today

    CRISPR Therapeutics' stock is jumping in response to a positive regulatory development for its lead therapy.

  • Investopedia5 days ago

    CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial

    The Food and Drug Administration (FDA) has cleared the way for CRISPR Therapeutics Ltd. ( CRSP) and Vertex Pharmaceuticals Inc. ( VRTX) to start testing their genetically engineered treatment for sickle cell disease on U.S. patients. In a press release, the two companies said the FDA has now lifted its clinical hold, enabling them to begin trailing the experimental therapy. At the time, CRISPR and Vertex claimed that CTX001 was placed on hold because the FDA had additional questions as part of its review of the paperwork that companies submit for permission to start a clinical trial.

  • CNBC5 days ago

    After-hours buzz: SQ, FLR & more

    Check out the companies making headlines after the bell: Square SQ stock tumbled 8 percent in after-hours trading following news that CFO Sarah Friar is stepping down . Friar will stay at the company until December before departing to become CEO of Nextdoor, a localized social network for neighborhoods.

  • FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
    American City Business Journals5 days ago

    FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial

    The FDA has lifted its hold on a highly anticipated gene-editing trial by CRISPR Therapeutics and Vertex Pharmaceuticals, allowing for the first company-backed trial in the U.S. to start by the end of the year.

  • MarketWatch5 days ago

    Crispr stock up 8% as company says FDA accepted new-drug application

    Shares of Crispr Therapeutics AG rose more than 8% in the extended session Wednesday after the company and Vortex Pharmaceuticals Inc. said the Food and Drug Administration has lifted a clinical hold and has accepted a new-drug application for their gene-editing treatment for sickle-cell disease. Shares of Vortex rose 0.6% after ending the regular trading day down 5%. Crispr shares closed 0.6% lower.

  • GlobeNewswire5 days ago

    CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

    In addition to the acceptance of the IND announced today, CRISPR and Vertex previously announced that they had obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both β-thalassemia and SCD. The companies remain on track to initiate a Phase 1/2 clinical study in SCD by the end of 2018 and are currently enrolling patients with transfusion dependent β-thalassemia in a Phase 1/2 trial in β-thalassemia in Europe. The elevation of HbF by CTX001 has the potential to alleviate transfusion-requirements for β-thalassemia patients and painful and debilitating sickle crises for sickle cell patients.

  • Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)
    Zacks6 days ago

    Why the Earnings Surprise Streak Could Continue for Vertex (VRTX)

    Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • 3 Biotech Stocks With Major Incoming Catalysts
    Motley Fool7 days ago

    3 Biotech Stocks With Major Incoming Catalysts

    These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist7 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • 7 Fast-Growing Stocks to Buy Today
    InvestorPlace10 days ago

    7 Fast-Growing Stocks to Buy Today

    For the past nearly 10 years, the Federal Reserve and all the central banks in all the industrialized nations have been managing interest rates to keep them outrageously low until the financial system had a chance to right itself. Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets.

  • Ionis Pharmaceuticals’ Revenue Growth Rate
    Market Realist13 days ago

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.

  • Business Wire15 days ago

    Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines

    Vertex Pharmaceuticals (Europe) Limited today announced it has entered into an innovative access contract with the Danish pharmaceutical and procurement organization, Amgros. Effective from today, this first-of-its-kind contract includes current and future CFTR modulator medicines, and means eligible Danish cystic fibrosis (CF) patients will have access to all current medicines as well as future medicines after regulatory approval.

  • How Vertex Pharmaceuticals Is Positioned Financially
    Market Realist17 days ago

    How Vertex Pharmaceuticals Is Positioned Financially

    In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million. Kalydeco, Orkambi, and Symdeko saw revenue of $253.0 million, $311.0 million, and $186.0 million, respectively, in Q2 2018, compared with $250.0 million, $354.0 million, and $34.0 million, respectively, in Q1 2018. Vertex’s revenue growth could boost the First Trust NYSE Arca Biotechnology Index ETF (FBT), of which Vertex comprises ~3.33%.

  • Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
    Market Realist17 days ago

    Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

    Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter. Vertex’s Orkambi, Kalydeco, and Symdeko are top drugs in the cystic fibrosis market. Vertex stock’s 52-week low is $136.50, which it reached on December 7, 2017.

  • Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV
    Motley Fool18 days ago

    Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV

    Which stock wins in a battle between these two biotechs?

  • Investor's Business Daily19 days ago

    Here's Why The Stock Market Sold Off After The Fed Meeting

    Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.

  • Investor's Business Daily19 days ago

    Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance

    In stock news today, strong showings from biotech stocks Alexion and Incyte lifted the Nasdaq 100 to a gain of nearly 1% in afternoon trading.

  • Is CRISPR Therapeutics AG a Buy?
    Motley Foollast month

    Is CRISPR Therapeutics AG a Buy?

    On one hand, there's the promise of a groundbreaking technology. On the other hand, huge risk. Which hand wins?

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX

  • 3 Top Healthcare Stocks to Buy in September
    Motley Foollast month

    3 Top Healthcare Stocks to Buy in September

    Hint: Think heart pumps, lab services, and cystic fibrosis drugs.